Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 1% glycopyrronium bromide cream in primary axillary hyperhidrosis
2017-004534-28Phase 3Completed
- Sponsor
- Dr. August Wolff
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium in essential axillary hyperhidrosis (3 arms), sponsored by Dr. August Wolff. Primary endpoints: Efficacy of 1% glycopyrronium bromide vs placebo after 4 weeks and Short-term safety of 1% glycopyrronium bromide vs placebo after 4 weeks. Started Mar 2018; status: completed.
02
Drugs
glycopyrronium
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on 2017-004534-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004534-28.